Galapagos

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mechelen, Belgium; 15 June 2023, 22:01 CET ; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of T had Huston as Chief Financial Officer (C F O) and Chief Operating Officer (C O O) as per 1 July 2023 . Mr. Huston will be a member of the Executive Committee of Galapagos and will join Galapagos from Kite, a Gilead C ompany (NASDAQ: GILD) . He brings 30 years of global finance and operational experience in healthcare with an excellent track record of driving business transformation and innovation.

Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer

Incyte

Mechelen, Belgium; 12 June 2023, 22:01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 12 June 2023 , the Board of Directors co-opted Dr. Susanne S chaffert as no n-executive independent Director. Dr. Schaffert replaces Dr. Rajesh Parekh who stepped down on 10 June 2023 .

Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board

Mechelen, Belgium ; 5 June 202 3 , 22 : 01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will feature the CAR-T point-of-care manufacturing platform and will present previously disclosed initial Phase 1/2 data with CD19 CAR-T candidate , GLPG5201 , at the European Hematology Association (EHA ) 2023 congress, taking place from 8 June to 11 June 2023 in Frankfurt , Germany.

Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress

Mechelen , Belgium; 2 3 May 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was dosed in GALARISSO, the Phase 2 dermatomyositis (DM) trial with GLPG3667.

Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis

Mechelen , Belgium; 22 May 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will present a broad range of abstracts, including analysis from randomized controlled trials (RCTs) and real-world evidence (RWE) studies at the European League Against Rheumatism (EULAR) annual congress taking place from 31 May to 3 June 2023 in Milan.

Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023

Galapagos' focuses on immunology and oncology, with its flagship Jyseleca being used to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan. The company is also developing CAR-T therapies with encouraging initial safety and efficacy data presented from ongoing Phase 1/2 studies.

Galapagos Stands Strong On Jyseleca Positive Clinical Data

Webcast presentation   tomorrow,   5   May 2023,   at 14 : 00 CET   /   8 :00 am ET,   www.glpg.com

Galapagos announces first quarter 2023 financial results

Mechelen, Belgium; 2 May 2023, 22:01 CET ; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the departure of Bart Filius , President, Chief Operating Officer and Chief Financial Officer .

Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer

Mechelen , Belgium; 26 April 202 3 , 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was randomized in OLINGUITO , the pivotal Phase 3 program of filgotinib in A xSpA . Topline results are expected in H2 2025 .

Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis

Mechelen, Belgium; 2 5 April 2023 , 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces the approval of all resolutions proposed at its annual shareholders' meeting (AGM) held today at 14.00 CET.

Galapagos' shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders' meeting

Mechelen, Belgium and Strasbourg, France ; 30 March 202 3 , 22.0 1 CET; Galapagos   NV (Euronext & NASDAQ: GLPG) and NovAliX today announced a strate g ic collaboration in which Galapagos' research and discovery capabilities and exclusively related employees based in Romainville , France , will be transferred to Nov A li X , a drug discovery-focused Contract Research Organization . The agreement follows Galapagos' renewed focus on its key therapeutic areas of oncology and immunology, and the strategic reorientation of the company into a fit-for-purpose research and development ( R&D ) organization which aims to accelerate innovation, reduce risks and shorten drug development timelines.

Galapagos and NovAliX enter into an integrated drug discovery collaboration

Mechelen, Belgium; 2 3 March 2023 , 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishe s its a nnual report for the financial year 202 2 and announces its A nnual S hareholders' M eeting , to be held on Tuesday 2 5 April 202 3 , at 2:00 p.m. (CET) , at the registered office of the company .

Galapagos publishes 2022 annual report and announces Annual Shareholders' Meeting

Mechelen, Belgium; 20 March 202 3 , 2 1 .01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises .

Galapagos increases share capital through subscription right exercises

Galapagos NV (NASDAQ:GLPG ) Q4 2022 Earnings Conference Call February 24, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director of Investor Relations Paul Stoffels - Chief Executive Officer Bart Filius - Chief Operating Officer & President Daniele D'Ambrosio - Head of Immunology Michele Manto - Chief Commercial Officer Conference Call Participants Phil Nadeau - Cowen Peter Verdult - Citi Brian Abrahams - RBC Capital Markets Rosie Turner - Jefferies Dane Leone - Raymond James Suzanne van Voorthuizen - Kempen Operator Good day and thank you for standing by. Welcome to the Galapagos Full Year 2022 Financial Results Call and Webcast.

Galapagos NV (GLPG) Q4 2022 Earnings Call Transcript

Galapagos announces full year 2022 results and outlook for 2023

On February 8th, 2023, Galapagos announced disappointing results of their phase 3 DIVERSITY Crohn's disease study; the company is no longer planning to file an MAA. Galapagos stock fell 8%, and the stock is still hovering around negative $2.0Bn enterprise value territory.

Galapagos: Crohn's Disease Trial Failure, Still Maintaining A Buy Rating

Mechelen, Belgium; 9 February 2023, 22.01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) today presented encouraging data at the European Society for Blood and Marrow Transplantation ( EBMT ) - European Hematology Association ( EHA ) 5 th European CAR T-cell Meeting in Rotterdam .

Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL

U.S.-listed shares of Galapagos GLPG, +0.41% were down 8.9% in premarket trading on Thursday, the day after the company said an experimental treatment for Crohn's disease missed the primary endpoints in a Phase 3 clinical trial. The drug, filgotinib, is approved to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan.

Galapagos shares down after announcing clinical-trial miss for Crohn's disease

Mechelen, Belgium ;  8 February 202 3 ,  22:01 CET; regulated information; Galapagos NV (Euronext & NASDAQ: GLPG) today   announced the topline results from DIVERSITY, a global Phase 3 trial to evaluate the safety and efficacy of filgotinib , 100mg or 200mg once daily, during induction and maintenance treatment of biologic-n aïve and biologic-experienced patients with moderate to severe Crohn's disease (CD) .

Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn's disease

Galapagos is a Belgiu- based commercial biotech, led by ex-J&J CSO Paul Stoffels. The company holds ~$4Bn cash and currently trading at a negative $1.8Bn enterprise value.

Galapagos: Deeply Into Negative EV Territory, Exciting BD Optionality, Buy

Mechelen, Belgium; 3 January 202 3 , 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 4 1t h Annual J.P. Morgan Healthcare Conference on January 9 -1 2 , 202 3 .

Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference

GLPG is setting to transform its business after a slew of failures. The new CEO is a global expert at this, and I don't see him failing.

Galapagos: Slow Transformation, But Led By An Expert

Pacira Pharmaceuticals

Vir Biotechnology

Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.

3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023

Mechelen, Belgium; 22 December 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced changes in the E xecutive Committee effective 1 January 2023 .

Galapagos announces changes to Executive Committee

The average of price targets set by Wall Street analysts indicates a potential upside of 34.4% in Galapagos NV (GLPG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

News for Galapagos Stock (GLPG)